Company | Name | Exchange | Sector | Industry | 3 Month | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shanghai Allist Pharmaceuticals Co | Shanghai | Healthcare | Biotechnology & Medical Research | 12.5% | CN¥26.64B | 19.8x | 0.12 | CN¥63.99 | 8.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.7% Upside | Upgrade to Pro+ | |
Dongxing Securities | Shanghai | Financial | Investment Banking & Investment Services | 4.4% | CN¥35.46B | 27.1x | 0.13 | CN¥11.08 | 4.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -19.6% Downside | Upgrade to Pro+ | |
Jiangsu Asieris Pharmaceuticals | Shanghai | Healthcare | Biotechnology & Medical Research | 3.7% | CN¥3.63B | -9x | 0.52 | CN¥6.71 | 3.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36% Upside | Upgrade to Pro+ | |
Ruida | Shenzhen | Financial | Investment Banking & Investment Services | -3.2% | CN¥5.92B | 20.1x | 0.4 | CN¥13.74 | 3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -11.3% Downside | Upgrade to Pro+ | |
Sichuan Biokin Pharmaceutical | Shanghai | Healthcare | Pharmaceuticals | -5% | CN¥75B | 21.3x | 0.02 | CN¥193.32 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40.5% Upside | Upgrade to Pro+ | |
Dizal Jiangsu Pharmaceutical | Shanghai | Healthcare | Biotechnology & Medical Research | -6.3% | CN¥16.60B | -18.5x | -0.9 | CN¥41.87 | 4.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40.2% Upside | Upgrade to Pro+ | |
Beigene | Shanghai | Healthcare | Biotechnology & Medical Research | -8.1% | CN¥11.51B | -0.3x | -1.4 | CN¥178.60 | 9.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.9% Upside | Upgrade to Pro+ | |
Shandong Cvicse Middleware | Shanghai | Technology | Software & IT Services | -10.3% | CN¥2.39B | 32.8x | 0.55 | CN¥29.29 | 4.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Chongqing Genrix Biopharmaceutical | Shanghai | Healthcare | Pharmaceuticals | -11.8% | CN¥8.47B | -11.4x | -1.22 | CN¥24.92 | 7.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Innovita Biological Tech | Shanghai | Healthcare | Healthcare Equipment & Supplies | -17.3% | CN¥4.56B | 14.9x | 0.08 | CN¥34.18 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
RemeGen | Shanghai | Healthcare | Biotechnology & Medical Research | -20.3% | CN¥11.28B | -5.5x | 0.4 | CN¥26.80 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.6% Upside | Upgrade to Pro+ | |
Holly Futures | Shenzhen | Financial | Investment Banking & Investment Services | -21.6% | CN¥2.42B | 104.4x | 1.23 | CN¥9.19 | 4.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |